全文获取类型
收费全文 | 4881篇 |
免费 | 259篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 58篇 |
儿科学 | 360篇 |
妇产科学 | 99篇 |
基础医学 | 607篇 |
口腔科学 | 109篇 |
临床医学 | 335篇 |
内科学 | 1191篇 |
皮肤病学 | 101篇 |
神经病学 | 179篇 |
特种医学 | 103篇 |
外科学 | 705篇 |
综合类 | 214篇 |
一般理论 | 1篇 |
预防医学 | 239篇 |
眼科学 | 171篇 |
药学 | 350篇 |
1篇 | |
中国医学 | 20篇 |
肿瘤学 | 310篇 |
出版年
2023年 | 33篇 |
2022年 | 36篇 |
2021年 | 159篇 |
2020年 | 80篇 |
2019年 | 145篇 |
2018年 | 160篇 |
2017年 | 112篇 |
2016年 | 133篇 |
2015年 | 147篇 |
2014年 | 191篇 |
2013年 | 230篇 |
2012年 | 367篇 |
2011年 | 359篇 |
2010年 | 209篇 |
2009年 | 171篇 |
2008年 | 271篇 |
2007年 | 290篇 |
2006年 | 226篇 |
2005年 | 188篇 |
2004年 | 192篇 |
2003年 | 164篇 |
2002年 | 160篇 |
2001年 | 95篇 |
2000年 | 101篇 |
1999年 | 82篇 |
1998年 | 41篇 |
1997年 | 18篇 |
1995年 | 15篇 |
1994年 | 21篇 |
1993年 | 18篇 |
1992年 | 63篇 |
1991年 | 71篇 |
1990年 | 54篇 |
1989年 | 63篇 |
1988年 | 37篇 |
1987年 | 43篇 |
1986年 | 36篇 |
1985年 | 36篇 |
1984年 | 19篇 |
1983年 | 27篇 |
1982年 | 32篇 |
1981年 | 19篇 |
1980年 | 17篇 |
1979年 | 24篇 |
1977年 | 13篇 |
1976年 | 23篇 |
1973年 | 18篇 |
1969年 | 13篇 |
1968年 | 13篇 |
1966年 | 14篇 |
排序方式: 共有5153条查询结果,搜索用时 15 毫秒
1.
2.
Objective
To determine the association between provider training level and postplacental intrauterine device (IUD) outcomes following insertion instruction by email only.Study design
We conducted a single-center chart review of demographics, insertion and clinical outcomes within 6 months of delivery for 116 patients who underwent postplacental levonorgestrel 52?mg IUD placement from October 1, 2016, to March 31, 2017.Results
We confirmed IUD retention, removal or expulsion in 87 of 116 (75.0%) patients by 6 months after delivery. Complete expulsion or removal for malposition occurred in 20 (23.0%) patients and more frequently after vaginal than cesarean delivery (30.2% vs. 4.2%, OR 9.93 [95% CI 1.25–78.96]) and when a postgraduate year (PGY) 1 physician placed the IUD compared to a PGY 2–4 or attending physician (37.5% vs. 14.5%, OR 3.52 [95% CI 1.25–9.94]).Conclusion
Postplacental levonorgestrel 52?mg IUD expulsion rates are associated with provider training level as well as delivery route, though the individual association of each of these factors is difficult to ascertain given the high degree of collinearity between these two variables in our study. 相似文献3.
4.
Objective
To empirically assess the effect of adopting Affordable Care Act's Community First Choice (CFC) option on overall state home and community-based services (HCBS) expenditures as well as distribution of HCBS expenditures across different HCBS mechanisms. We also explore the heterogeneous effect of CFC across adopting states.Data Source
We used data from the Medicaid Long Term Services and Support (LTSS) expenditure reports prepared by Truven Analytics and Mathematica for the Centers for Medicare & Medicaid Services from 2008–2018 for all 48 states and the District of Columbia.Study Design
An event-study difference-in-differences model was used to estimate the effect of CFC on HCBS expenditures using Medicaid LTSS expenditure reports from 2008–2018. We also employ the synthetic control method to unmask heterogeneity across CFC adopting states using data from 2008–2018.Data Collection/Extraction Methods
Not applicable.Principal Findings
Overall, CFC was not associated with a change in HCBS expenditures per capita or HCBS expenditures as a proportion of LTSS expenditures. However, there appears to be an increase in HCBS expenditures among states that were institutionally-oriented prior to CFC adoption. Additionally, CFC adoption was associated with an overall decrease in expenditures in alternative HCBS mechanisms (Personal Care Services State Plan Option and 1915(c) waivers), suggesting potential substitution across overlapping programs.Conclusion
Results indicate heterogeneity across states adopting CFC. More institutionally-oriented states appear to use CFC to expand HCBS. In contrast, more HCBS-oriented states appear to employ CFC to strategically restructure their overall portfolio and processes. 相似文献5.
Kirandeep Kaur Rashi Sharma Atamjit Singh Shivani Attri Saroj Arora Sarabjit Kaur Neena Bedia 《中草药(英文版)》2022,14(4):511-527
Alkannin/shikonin (A/S) and their derivatives are naturally occurring naphthoquinones majorly found in Boraginaceae family plants. They are integral constituents of traditional Chinese medicine Zicao (roots of Lithospermum erythrorhizon). In last two decades significant increase in pharmacological investigations on alkannin/shikonin and their derivatives has been reported that resulted in discovery of their novel mechanisms in various diseases and disorders. This review throws light on recently conducted pharmacological investigations on alkannin/shikonin and their derivatives and their outputs. Various analytical aspects are also discussed and brief summary of patent applications on inventions containing alkannin/shikonin and its derivatives is also provided. 相似文献
6.
7.
8.
9.
Sameer Arora Kamal Shemisa Muthiah Vaduganathan Arman Qamar Ankur Gupta Sushil K. Garg Dharam J. Kumbhani Helen Mayo Houman Khalili Ambarish Pandey Sandeep R. Das 《Journal of the American College of Cardiology》2019,73(19):2454-2464
Ticagrelor is a cornerstone of modern antithrombotic therapy alongside aspirin in patients with acute coronary syndrome and after percutaneous coronary intervention. Adverse effects such as bleeding and dyspnea have been associated with premature ticagrelor discontinuation, which may limit any potential advantage of ticagrelor over clopidogrel. The randomized trials of ticagrelor captured adverse events, offering the opportunity to more precisely quantify these effects across studies. Therefore, a meta-analysis of 4 randomized clinical trials of ticagrelor conducted between January 2007 and June 2017 was performed to quantify the incidence and causes of premature ticagrelor discontinuation. Among 66,870 patients followed for a median 18 months, premature ticagrelor discontinuation was seen in 25%; bleeding was the most common cause of discontinuation followed by dyspnea. Versus the comparators, the relative risk of dyspnea-related discontinuation during follow-up was 6.4-fold higher, the relative risk of bleeding was 3.2-fold higher, and the relative risk of discontinuation due to any adverse event was 59% higher for patients receiving ticagrelor. Understanding these potential barriers to adherence to ticagrelor is crucial for informed patient-physician decision making and can inform future efforts to improve ticagrelor adherence. This review discusses the incidence, causes, and biological mechanisms of ticagrelor-related adverse effects and offers strategies to improve adherence to ticagrelor. 相似文献
10.
Arunaloke Chakrabarti Prashant Sood Shivaprakash M. Rudramurthy Sharon Chen Joseph Jillwin Ranganathan Iyer Ajanta Sharma Belgode Narasimha Harish Indranil Roy Anupma J. Kindo Deepinder Chhina Jayanthi Savio Deepak Mendiratta Malini R. Capoor Shukla Das Anita Arora Jagdish Chander Immaculata Xess Appalaraju Boppe Ujjwayini Ray Ratna Rao Vandana Kalwaje Eshwara Sangeeta Joshi Atul Patel Raman Sardana Anjali Shetty Umabala Pamidimukkala for the SIHAM Candidemia Network 《Mycoses》2020,63(11):1149-1163